Eli Lilly and Company has completed its $3.2-billion acquisition of Morphic, a Waltham, Massachusetts-based bio/pharmaceutical company developing oral integrin therapies for treating chronic diseases. The deal was announced in July 2024. 

Morphic’s lead program is Morf-057, an oral drug for treating inflammatory bowel disease. It is being evaluated in two Phase II studies in ulcerative colitis and one Phase II study in Crohn’s disease. Additionally, Morphic is developing a preclinical pipeline of other molecules for treating autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases, and cancer. 

Lilly acquired 46,731,511 shares of Morphic for a 92.8% stake of the company and completed the acquisition through a previously planned second-step merger.  

Source: Eli Lilly and Company